drugset / Trial / NCT01009437
Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer
Phase 1
Completed
28 enrolled
Masonic Cancer Center, University of Minnesota
Susan G. Komen Breast Cancer Foundation · collab
Non-randomizedSingle-groupOpen-labelDiagnostic
Summary
RATIONALE: Ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cancer cell growth. Studying samples of blood and tissue from patients with breast cancer in the laboratory may help doctors learn more about the effects of ritonavir on biomarkers involved in breast cancer growth. PURPOSE: This phase I/II trial is studying the best dose of ritonavir and its effects on biomarkers in women undergoing surgery for newly diagnosed breast cancer.
Timeline
- Start
- 2010-05-26
- Primary completion
- 2014-07
- Completion
- 2014-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ritonavir | Other / unclassified | 200 mg | Oral |
| Subject | Ritonavir | Other / unclassified | 400 mg | Oral |
| Subject | Ritonavir | Other / unclassified | 600 mg | Oral |